Patient Capital Doubles Down on Precigen, Acquires 10.2 Million Shares

Patient Capital Management acquired 10.2 million Precigen (PGEN) shares, valued at $28.78 million, in Q3 2025, increasing its stake to 26.5 million shares worth $87.06 million. This represents 1.15% of the fund's assets under management and 3.48% of its portfolio, making it a significant holding outside the top five. The stock price has surged by 375.91% over the past year, outperforming the S&P 500 by 356.34 percentage points.